3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase EARLY_PHASE1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Myeloid
1
Conditions
Lymphoma
16
Lymphoma, Non-Hodgkin
11
Lymphoma, Large B-Cell, Diffuse
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Leukemia, Lymphocytic, Chronic, B-Cell
7
Hodgkin Disease
7
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, B-Cell, Marginal Zone
6
Leukemia, Myeloid, Acute
6
Lymphoma, Mantle-Cell
5
Lymphoma, Follicular
5
Small Cell Lung Carcinoma
4
Neuroblastoma
4
Burkitt Lymphoma
4
Testicular Neoplasms
3
Sarcoma
3
Lymphoma, T-Cell
3
Leukemia
3
Central Nervous System Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Waldenstrom Macroglobulinemia
2
Testicular Germ Cell Tumor
2
Teratoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Osteosarcoma
2
Neoplasms, Germ Cell and Embryonal
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Interventions
Bevacizumab
10
Magnetic Resonance Spectroscopy
9
Temozolomide
8
Cyclophosphamide
8
Etoposide
7
X-Rays
6
Phantoms, Imaging
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Cisplatin
5
Radiotherapy
4
Irinotecan
4
Filgrastim
4
Carboplatin
4
Biopsy
4
Erlotinib Hydrochloride
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
sargramostim
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
etoposide phosphate
2
erdafitinib
2
ensartinib
2
Vincristine
2
Vemurafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Ependymoma
×
etoposide phosphate
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled